CLEARSIDE BIOMEDICAL INC. - COMMON STOCK

Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023

31 Oct 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

16 Oct 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China

04 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit

03 Oct 2023 15:35:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare Conference

19 Sep 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update

14 Aug 2023 15:05:01 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Upcoming Investor Conferences in August 2023

02 Aug 2023 15:30:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Monday, August 14, 2023

01 Aug 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation at the American Society of Retina Specialists 41st Annual Scientific Meeting

31 Jul 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings

20 Jul 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Enrollment of Multiple Participants in its ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

17 Jul 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical CEO George Lasezkay to Present at the SHARE™️ Series Investor Event on Monday, July 17, 2023

11 Jul 2023 15:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema

10 Jul 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

01 Jun 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update

11 May 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in a Fireside Chat at the JMP Securities Life Sciences Conference

09 May 2023 15:30:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023

02 May 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Presents Compelling Data at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

27 Apr 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

19 Apr 2023 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Plans for ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

18 Apr 2023 06:05:00 By Nasdaq GlobeNewswire